All In Biotech

Drug Trial Radar · NCT05939700

Mavacamten Pregnancy Surveillance Program

Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 9, 2023

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 11, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 15 years

Summary

As written by the sponsor on the registry.

The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.

Conditions

  • Breastfeeding
  • Hypertrophic Cardiomyopathy
  • Pregnancy Related

Interventions

  • MavacamtenDrug

    Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy outcomesTime frame: Up to 10 months
  2. Fetal/neonatal/infant outcomesTime frame: Up to 12 months post pregnancy outcome

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Mavacamten Pregnancy Surveillance Program, PPD Inc

    Wilmington, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.